Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,129B 70.25B 60.96B 57.09B 52.22B 98.58B 6,692B 99.87B 668B 262B 3,344B 264B 258B P/E 2026 *
21.9x
P/E 2027 * 18.8x
Enterprise Value 10,219B 64.51B 55.98B 52.42B 47.95B 90.52B 6,145B 91.7B 613B 241B 3,070B 242B 237B EV / Sales 2026 *
7.35x
EV / Sales 2027 * 6.47x
Free-Float
38.12%
Yield 2026 *
2.01%
Yield 2027 * 2.3%
1 day+1.37%
1 week-1.08%
Current month-1.08%
1 month-10.01%
3 months-15.29%
6 months-24.86%
Current year-16.81%
1 week 6,575
Extreme 6575
6,857
1 month 6,575
Extreme 6575
7,762
Current year 6,575
Extreme 6575
10,700
1 year 5,942
Extreme 5942
10,700
3 years 4,156
Extreme 4156
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 28/02/2021
Director of Finance/CFO 59 27/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 29/02/2020
Director/Board Member 59 27/03/2024
Director/Board Member 51 28/02/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-1.08%-7.34%+64.16% 70.25B
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+2.48%+5.66%+49.98%+41.06% 358B
+1.30%+0.21%+36.34%+41.19% 293B
+1.31%-4.85%+9.76%+10.41% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+4.27%+0.08%-0.68%-43.79% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +0.93%-2.14%+28.35%+52.80% 366.25B
Weighted average by Cap. +0.51%-0.89%+40.35%+78.13%

Financials

2026 *2027 *
Net sales 1,391B 8.78B 7.62B 7.14B 6.53B 12.32B 836B 12.48B 83.47B 32.76B 418B 32.97B 32.25B 1,541B 9.73B 8.44B 7.91B 7.23B 13.65B 927B 13.83B 92.48B 36.29B 463B 36.53B 35.73B
Net income 508B 3.21B 2.78B 2.6B 2.38B 4.5B 305B 4.56B 30.47B 11.96B 153B 12.03B 11.77B 592B 3.74B 3.24B 3.04B 2.78B 5.25B 356B 5.31B 35.54B 13.95B 178B 14.04B 13.73B
Net Debt -910B -5.75B -4.99B -4.67B -4.27B -8.06B -547B -8.17B -54.62B -21.44B -273B -21.57B -21.1B -1,152B -7.27B -6.31B -5.91B -5.41B -10.2B -693B -10.34B -69.13B -27.13B -346B -27.3B -26.71B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
07/08/26 JP¥6,857.00 +1.37% 1,897,700
06/08/26 JP¥6,764.00 +1.14% 3,147,300
05/08/26 JP¥6,688.00 +0.12% 2,782,100
04/08/26 JP¥6,680.00 -0.10% 3,013,700
03/08/26 JP¥6,687.00 -3.53% 3,532,400
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,764.00JPY
Average target price
9,513.33JPY
Spread / Average Target
+40.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4519 Stock